NCT04576091 2024-12-13Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerNational Cancer Institute (NCI)Phase 1 Active not recruiting7 enrolled